Earlier this month, research outcomes confirmed that molnupiravir, Merck’s investigational antiviral tablet, reduce hospitalization charges of Covid-19 sufferers by about half. Molnupiravir is the primary oral therapy that has proven promise in treating Covid-19. One other antiviral, remdesivir, can solely be administered intravenously.
“Having an oral possibility will likely be an enormous change,” stated Benjamin Gewurz, affiliate director of the Ph.D. program in virology at Harvard Medical College. “Some individuals might simply take a tablet reasonably than having an IV or injection of some type. And that’s what can be an enormous, big advance.”
This video explains precisely how this drug works within the physique to fight the coronavirus.